[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR057242A2 - Composicion farmaceutica para administracion oral y uso de la misma en la fabricacion de un medicamento - Google Patents

Composicion farmaceutica para administracion oral y uso de la misma en la fabricacion de un medicamento

Info

Publication number
AR057242A2
AR057242A2 ARP060105534A ARP060105534A AR057242A2 AR 057242 A2 AR057242 A2 AR 057242A2 AR P060105534 A ARP060105534 A AR P060105534A AR P060105534 A ARP060105534 A AR P060105534A AR 057242 A2 AR057242 A2 AR 057242A2
Authority
AR
Argentina
Prior art keywords
manufacture
pharmaceutical composition
oral administration
compound
same
Prior art date
Application number
ARP060105534A
Other languages
English (en)
Inventor
Jean Francois Rossignol
Original Assignee
Romark Lab Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057242(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/852,447 external-priority patent/US5968961A/en
Priority claimed from US08/887,809 external-priority patent/US5965590A/en
Priority claimed from US08/887,810 external-priority patent/US5856348A/en
Application filed by Romark Lab Lc filed Critical Romark Lab Lc
Publication of AR057242A2 publication Critical patent/AR057242A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composicion farmacéutica para administracion oral, caracterizada porque comprende como agente activo por lo menos un compuesto seleccionado del grupo integrado por: el compuesto de formula (1) y el compuesto de la formula (2) y un ácido farmacéuticamente aceptable para mejorar la estabilidad. También se revela el uso de estas composiciones en la fabricacion de un medicamento para tratar una infeccion provocada por un microorganismo seleccionado del grupo integrado por: Cryptosporidium parvum, isospora belli, Enterocytozoon bíeneusi, Encephalistozoon intestinalis, Mycobacterium tuberculosis, Mycobacterium avium intracellulare, Pneumocystis carinii y Toxoplasma gondii e infecciones parasitarias provocadas por trematodos.
ARP060105534A 1997-05-07 2006-12-14 Composicion farmaceutica para administracion oral y uso de la misma en la fabricacion de un medicamento AR057242A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/852,447 US5968961A (en) 1997-05-07 1997-05-07 Pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,809 US5965590A (en) 1994-09-08 1997-07-03 Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,810 US5856348A (en) 1994-09-08 1997-07-03 Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide

Publications (1)

Publication Number Publication Date
AR057242A2 true AR057242A2 (es) 2007-11-21

Family

ID=27420362

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105534A AR057242A2 (es) 1997-05-07 2006-12-14 Composicion farmaceutica para administracion oral y uso de la misma en la fabricacion de un medicamento

Country Status (35)

Country Link
EP (2) EP1222921B1 (es)
JP (1) JP3739802B2 (es)
KR (2) KR100576646B1 (es)
CN (2) CN100515420C (es)
AP (1) AP1103A (es)
AR (1) AR057242A2 (es)
AT (2) ATE228839T1 (es)
AU (1) AU740022B2 (es)
BG (2) BG109365A (es)
BR (1) BR9808722A (es)
CA (2) CA2288003C (es)
CZ (2) CZ298270B6 (es)
DE (2) DE69827417T2 (es)
DK (2) DK1005342T3 (es)
EA (2) EA002920B1 (es)
EE (1) EE04870B1 (es)
ES (2) ES2150404T3 (es)
GE (1) GEP20032970B (es)
HK (1) HK1025907A1 (es)
HU (1) HU229641B1 (es)
IL (2) IL132516A (es)
IS (1) IS2087B (es)
LV (1) LV12492B (es)
ME (1) ME00530B (es)
NO (2) NO313983B1 (es)
NZ (2) NZ513881A (es)
OA (1) OA11169A (es)
PL (1) PL193275B1 (es)
PT (2) PT1005342E (es)
RO (1) RO120605B1 (es)
SI (1) SI20149B (es)
SK (2) SK283947B6 (es)
TR (1) TR199902733T2 (es)
UA (2) UA57079C2 (es)
WO (1) WO1998050035A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2467321A1 (en) 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
CN101448497B (zh) 2006-01-09 2013-07-10 罗马克实验室有限公司 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用
EP2395840B1 (en) * 2009-02-13 2020-04-15 Romark Laboratories, L.C. Controlled release pharmaceutical formulations of nitazoxanide
AU2010247816B2 (en) 2009-05-12 2015-12-17 Romark Laboratories L.C. Haloalkyl heteroaryl benzamide compounds
AP2012006064A0 (en) 2009-06-26 2012-02-29 Romark Lab Lc Compounds and methods for treating influenza.
WO2013110975A1 (es) 2012-01-27 2013-08-01 Siegfried Rhein S.A. De C.V. Composición de nitazoxanida mejorada y proceso para prepararla
EP3217795A4 (en) * 2014-11-11 2018-08-22 Romark Laboratories, L.C. Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
JP7502186B2 (ja) 2018-02-02 2024-06-18 リップル セラピューティクス コーポレーション ステロイド二量体を含むガラス製剤およびその使用
CN115956083A (zh) 2020-05-01 2023-04-11 波纹疗法公司 异二聚体组合物及用于治疗眼部病症的方法
WO2022130406A1 (en) * 2020-12-15 2022-06-23 Cipla Limited Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen

Also Published As

Publication number Publication date
HUP0003330A2 (hu) 2001-05-28
NO20021832D0 (no) 2002-04-18
AU7289598A (en) 1998-11-27
CN1158074C (zh) 2004-07-21
IS5223A (is) 1999-10-19
IL155799A0 (en) 2003-12-23
CA2288003C (en) 2003-10-21
CZ298270B6 (cs) 2007-08-08
NZ500149A (en) 2001-11-30
EA200100956A1 (ru) 2002-02-28
NZ513881A (en) 2002-10-25
EA199901012A1 (ru) 2000-08-28
KR100576646B1 (ko) 2006-05-08
JP3739802B2 (ja) 2006-01-25
BR9808722A (pt) 2000-07-11
SK151199A3 (en) 2000-07-11
CZ298269B6 (cs) 2007-08-08
OA11169A (en) 2003-04-25
EP1222921A1 (en) 2002-07-17
JP2001503067A (ja) 2001-03-06
EP1005342A1 (en) 2000-06-07
IL155799A (en) 2004-08-31
ATE228839T1 (de) 2002-12-15
IL132516A0 (en) 2001-03-19
LV12492A (en) 2000-06-20
RO120605B1 (ro) 2006-05-30
TR199902733T2 (xx) 2000-03-21
ES2232687T3 (es) 2005-06-01
DE69827417T2 (de) 2005-10-27
ATE281166T1 (de) 2004-11-15
EE9900578A (et) 2000-08-15
ES2150404T1 (es) 2000-12-01
AP1103A (en) 2002-09-04
DK1222921T3 (da) 2005-03-07
CN1552322A (zh) 2004-12-08
KR100426657B1 (ko) 2004-04-13
ES2150404T3 (es) 2003-07-01
EP1005342B1 (en) 2002-12-04
BG103958A (en) 2000-07-31
NO995406D0 (no) 1999-11-04
IL132516A (en) 2003-12-10
CA2418634A1 (en) 1998-11-12
NO20021832L (no) 2000-01-04
HK1025907A1 (en) 2000-12-01
PT1005342E (pt) 2003-02-28
CN1255060A (zh) 2000-05-31
SK283947B6 (sk) 2004-05-04
EP1005342A4 (en) 2001-02-07
NO995406L (no) 2000-01-04
IS2087B (is) 2006-03-15
LV12492B (en) 2001-01-20
PL193275B1 (pl) 2007-01-31
SI20149A (sl) 2000-08-31
HU229641B1 (en) 2014-03-28
DE69827417D1 (de) 2004-12-09
HUP0003330A3 (en) 2002-10-28
CA2288003A1 (en) 1998-11-12
GEP20032970B (en) 2003-05-27
SK283946B6 (sk) 2004-05-04
EA002920B1 (ru) 2002-10-31
DE69809928D1 (de) 2003-01-16
KR20010020322A (ko) 2001-03-15
PT1222921E (pt) 2005-02-28
NO335781B1 (no) 2015-02-16
EP1222921B1 (en) 2004-11-03
AU740022B2 (en) 2001-10-25
BG64973B1 (bg) 2006-11-30
AP9901675A0 (en) 1999-12-31
CA2418634C (en) 2004-10-26
SI20149B (en) 2001-08-31
BG109365A (en) 2006-08-31
DE69809928T2 (de) 2003-04-24
UA57079C2 (uk) 2003-06-16
NO313983B1 (no) 2003-01-13
PL336805A1 (en) 2000-07-17
KR20040004544A (ko) 2004-01-13
EA002908B1 (ru) 2002-10-31
UA74388C2 (uk) 2005-12-15
WO1998050035A1 (en) 1998-11-12
EE04870B1 (et) 2007-08-15
CZ391199A3 (cs) 2000-07-12
DK1005342T3 (da) 2003-03-24
ME00530B (me) 2011-10-10
CN100515420C (zh) 2009-07-22

Similar Documents

Publication Publication Date Title
AR057242A2 (es) Composicion farmaceutica para administracion oral y uso de la misma en la fabricacion de un medicamento
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
EP0379147A3 (en) Extrudable elastic gel for use as carrier for therapeutic agent
BR9810320A (pt) Composição farmacêutica sólida, contendo derivados de benzofurano
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
DE50005515D1 (de) Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen
HUP0100801A2 (hu) Metformin és fibrát kombinációját tartalmazó gyógyászati készítmények és ezek alkalmazása kórosan magas vércukorszint csökkentését célzó gyógyszerek előállítására
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ES2159591T3 (es) Composicion de liberacion controlada.
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
KR920702220A (ko) 산화적 손상에 관련된 질병을 억제하기 위한 방법 및 그 조성물
BRPI9708706C8 (pt) composição farmacêutica para administração intravenosa a um paciente
CO4950538A1 (es) Composiciones farmaceuticas de la tizoxadina y la nitazoxadina
CA2385890A1 (en) Controlled release compositions comprising nimesulide
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
WO2004108162A3 (en) Controlled release pharmaceutical composition
TR200101088T2 (tr) Sürekli salınımlı farmasötik kompozisyon ve farmasötik olarak aktif ajanın salınma metodu
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
MX9400801A (es) Agentes colinergicos de oxima de tetrahidropiridinna o-substituidos estabilizados con almidon.
RS51154B (sr) Farmaceutske kompozicije koje sadrže niske koncentracije peroksida za lečenje i sprečavanje vaginalnih infekcija
CO5160272A1 (es) Combinacion de cerivastatina y fibratos
AR002701A1 (es) Composición transdermica, uso y dispositivo estabilizado.
DE69928806D1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
BR0014440A (pt) Formulações de liberação controlada oral
HRP20020258B1 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive

Legal Events

Date Code Title Description
FC Refusal